T

he Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to JWL-Boston Cancel reply

Please enter your name.
Please enter a comment.

  • Who will pay for this drug? This is more like a ransom than business: your money or your life. The federal government (taxpayers) have already paid for the R&D through foregone taxes. I suspect the feds have also helped pay for the research directly by subsidies. They usually do. Now governments are pressured to pay for them again while CEOs make tens of millions a year and the drug companies spend more on administration and marketing than they do on R&D. When will America wake up? People are fed up being ripped off again and again. Now it’s pay for this or die.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.